NICM
KYMR icon

Neo Ivy Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Neo Ivy Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,033
Closed -$2.25M – 434
2026
Q1 		$2.25M Buy
+27,033
New +$2.14M 0.59% 63
2025
Q4 		– Sell
-19,660
Closed -$1.11M – 448
2025
Q3 		$1.11M Sell
19,660
-839
-4% -$37.8K 0.27% 130
2025
Q2 		$895K Buy
20,499
+6,079
+42% +$209K 0.29% 129
2025
Q1 		$395K Buy
+14,420
New +$526K 0.13% 208

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Neo Ivy Capital Management's KYMR Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 27,033 shares — an estimated $2.25M sold.

Neo Ivy Capital Management first reported a position in KYMR in Q1 2025 and held it in 4 quarters. The position peaked at $2.25M in Q1 2026. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 27,033 Kymera Therapeutics shares in Q2 2026, an estimated $2.25M.
  • Neo Ivy Capital Management first reported a position in Kymera Therapeutics in Q1 2025 and held it in 4 quarters.
  • Neo Ivy Capital Management's Kymera Therapeutics position peaked at $2.25M in Q1 2026.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.